After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could take to “maximizing stockholder value.”
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a narcolepsy drug and CDMO Avid Bioservices agreed to be taken private.
Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate if given a role in the incoming Trump administration.
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
Crea tu propia fuente de noticias
¿Listo para probarlo?
Comienza una prueba de 14 días, no es necesaria tarjeta de crédito.